Page 1372 - Clinical Small Animal Internal Medicine

1310 Section 11 Oncologic Disease

especially for surgical planning. Evaluation of possible carcinoma in veterinary patients are lacking. Toceranib
VetBooks.ir tumor extension into the vena cava is important if sur- phosphate, a multikinase receptor inhibitor similar to
sunitinib, is approved for mast cell neoplasia in veteri-
gery is considered.
The reported median survival time for dogs with
metastatic renal carcinoma.
renal cell carcinoma treated with nephrectomy is eight nary patients and may be considered for the treatment of
months. Standardized chemotherapy as an adjunct or in Chemotherapy treatment for renal lymphoma is simi-
the metastatic setting for renal carcinoma has not been lar to protocols used to treat lymphoma in other organs.
well defined. In humans, sunitinib, a multikinase recep- Approximately 60% of cats achieve complete remission.
tor inhibitor, has shown antitumor activity against meta- Negative prognostic factors included involvement of
static renal cell carcinoma. At this time, controlled other organ system (CNS), FeLV infection, and severity
studies using tyrosine kinase inhibitors against renal of renal failure.

Further Reading

Knapp DW. Tumors of the urinary system. In: Withrow S, Pressler BM. Cancer and the kidney In: Scansen B,
Vail D, Page R, eds. Withrow and MacEwen’s Small Bonagura J, eds. Kirk and Bonagura’s Current
Animal Clinical Oncology, 5th edn. St Louis, MO: Veterinary Therapy XVI. St Louis, MO: Elsevier, 2009,
Elsevier, 2013, pp. 572–81. pp. 925–30.